Neoadjuvant therapy for pancreatic cancer: the Duke experience.


Journal Article (Review)

The advantages of neoadjuvant (preoperative) chemoradiation therapy for pancreatic cancer include the assurance that all resected patients receive multimodality therapy; the opportunity for patients with occult metastatic disease to manifest themselves; and the potential to improve resectability. Since 1994, Duke University Medical Center has treated over 180 patients with localized pancreatic cancer using neoadjuvant 5-fluorouracil (5FU)-based chemoradiation therapy (CRT). Approximately 20% of patients demonstrate distant disease progression during CRT and avoid the morbidity of laparotomy. Almost 20% of locally advanced tumors on initial-staging CT can be resected following CRT. Patients who have successfully undergone resection have experienced favorable survival with an estimated 5-year survival rate of 36%. This article reviews the authors' experience and the lessons learned from it.

Full Text

Cited Authors

  • White, RR; Tyler, DS

Published Date

  • October 2004

Published In

Volume / Issue

  • 13 / 4

Start / End Page

  • 675 - x

PubMed ID

  • 15350941

Pubmed Central ID

  • 15350941

Electronic International Standard Serial Number (EISSN)

  • 1558-5042

International Standard Serial Number (ISSN)

  • 1055-3207

Digital Object Identifier (DOI)

  • 10.1016/j.soc.2004.06.001


  • eng